NCT03491371View on ClinicalTrials.gov

Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

February 1, 2017

Conditions
EfficacyToxicity
Interventions
DRUG

Methylsulfonic apatinib

Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.

Trial Locations (2)

100044

Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing

100144

Peking University Shougang Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Shougang Hospital

OTHER

collaborator

Peking University International Hospital

OTHER

lead

Peking University People's Hospital

OTHER

NCT03491371 - Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use | Biotech Hunter | Biotech Hunter